The Nasdaq late-filing notice is the dominant event — monitor for the 10-Q filing within the grace period (typically 60 days) or risk delisting. The EPS beat is immaterial for a pre-revenue biotech; the stock will trade on compliance news and FLAMINGO-01 trial updates.
Price Chart
Executive Summary
Greenwich LifeSciences reported Q3 2025 EPS of -$0.30, beating consensus of -$0.32 by 6.3%, but the press release primarily discloses a Nasdaq late-filing notice for its Q1 2026 10-Q, creating a bearish overhang. The company remains a pre-revenue clinical-stage biotech with no revenue, and the late filing raises compliance risk despite the modest EPS beat.
Key Financial Metrics
Key Facts
- Q3 2025 EPS of -$0.30 beat consensus of -$0.32 by 6.3%
- No revenue reported; company is pre-revenue clinical-stage
- Received Nasdaq notice for failure to file Q1 2026 10-Q on time (Listing Rule 5250(c)(1))
- Late filing has no immediate effect on listing but creates compliance risk
- Phase III FLAMINGO-01 trial for GLSI-100 immunotherapy ongoing
Financial Impact
EPS beat of $0.02 vs consensus, but no revenue; late filing risk overshadows
Risk Factors
- Potential delisting if 10-Q not filed within Nasdaq grace period
- No revenue or near-term catalyst from FLAMINGO-01 (Phase III, years from readout)
- Cash burn rate unknown; financing risk for clinical-stage company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300368 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEFA14A | $17.01 | awaiting T+5 | — | $16.89 (−0.73%) |
Oct 26, 2026 today | DEF 14A | $17.28 | awaiting T+5 | — | $16.89 (−2.26%) |
Aug 10, 2026 11w ago | Press Release | $15.50 $17.38 | ▲ +12.13% | ▲ +12.18% | $16.89 (+8.97%) |
Jul 30, 2026 12w ago | Insider Buy | $14.02 $14.24 | ▲ +1.57% | ▼ −2.05% | $16.89 (+20.47%) |
Jul 29, 2026 12w ago | Insider Buy | $12.80 $14.39 | ▲ +12.42% | ▲ +6.89% | $16.89 (+31.95%) |
May 22, 2026 22w ago | Press Release | $27.39 $24.29 | ▲ +11.32% | ▲ +12.53% | $16.89 (+38.34%) |
Apr 22, 2026 26w ago | Press Release | $23.67 $21.60 | ▲ +8.75% | ▲ +10.22% | $16.89 (+28.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers